Your Good Partner in Biology Research

乳腺癌

乳腺癌是一种起源于乳腺上皮细胞的恶性肿瘤,是女性中最常见的癌症之一,也是导致女性癌症死亡的主要原因之一。乳腺癌的发病率与多种因素有关,包括遗传、年龄、激素水平、生活方式等。根据肿瘤细胞的特征,乳腺癌可以分为不同的亚型,如激素受体阳性(ER+/PR+)、人表皮生长因子受体2(HER2+)和三阴性乳腺癌(TNBC)等。

近年来,乳腺癌的治疗和药物研发取得了显著进展。特别是在靶向治疗和免疫治疗领域,新药物和新疗法的不断涌现为患者带来了更多的治疗选择和更好的预后。

靶向治疗药物

● HER2阳性乳腺癌

HER2阳性乳腺癌的治疗在过去几年中取得了重大进展。ADC(抗体药物偶联物)类药物治疗是HER2阳性乳腺癌治疗的重要突破。例如,DS-8201(Trastuzumab Deruxtecan)是一种针对HER2的ADC药物,已经在临床试验中显示出对HER2低表达和HER2阴性乳腺癌患者的潜在疗效67。此外,T-DM1(Trastuzumab Emtansine)和T-DXd(Trastuzumab Deruxtecan)也在HER2阳性乳腺癌的治疗中取得了成功。

● 激素受体阳性乳腺癌

对于激素受体阳性的乳腺癌,CDK4/6抑制剂如阿贝西利(Abemaciclib)、达尔西利(Dalpiciclib)和瑞波西利(Ribociclib)等药物的开发为患者提供了新的治疗选择。这些药物通过抑制细胞周期的关键调节因子,减缓肿瘤细胞的生长和扩散。

● 三阴性乳腺癌

三阴性乳腺癌(TNBC)是一种较为难治的亚型,因为它缺乏激素受体和HER2的表达。然而,免疫治疗在这一领域取得了进展,例如PD-1/PD-L1抑制剂在TNBC的治疗中显示出潜力。

免疫治疗药物

免疫治疗是乳腺癌治疗领域的另一个重要进展。免疫检查点抑制剂,如PD-1和PD-L1抑制剂,已经在三阴性乳腺癌的治疗中显示出一定的疗效。此外,研究者正在探索将免疫治疗与其他治疗方法结合使用的策略,以提高治疗效果。

乳腺癌药物靶点相关产品推荐

● 靶点蛋白

CSB-MP007763HU Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.

CSB-MP619964HU1 Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.

CSB-MP878942HU1 Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL

CSB-MP023072HU1 Activity Verified

Measured in cell activity assay using U937 cells, the EC50 for this effect is 190.2-298.6 ng/ml.

CSB-MP007765HU Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.

CSB-MP006163HU1 Activity Verified

Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.

CSB-MP004940HU Activity Verified

Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.

CSB-MP007479HU Activity Verified

Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.

产品名称 货号 靶点 来源 蛋白标签
Recombinant Human Programmed cell death 1 ligand 1 (CD274), partial (Active) CSB-MP878942HU1 CD274 Mammalian cell C-terminal hFc-tagged
Recombinant Human CD276 antigen (CD276), partial (Active) CSB-MP733578HU CD276 Mammalian cell C-terminal hFc-Myc-tagged
Recombinant Human Tumor necrosis factor receptor superfamily member 5 (CD40), partial (Active) CSB-MP004936HU1 CD40 Mammalian cell C-terminal hFc-tagged
Recombinant Macaca fascicularis CD44 antigen (CD44), partial (Active) CSB-MP4290MOV CD44 Mammalian cell C-terminal 10xHis-tagged
Recombinant Human CD44 antigen (CD44), partial, Biotinylated (Active) CSB-MP004938HU(F1)j1-B CD44 Mammalian cell C-terminal mFc-Avi-tagged
Recombinant Human CD44 antigen (CD44), partial (Active) CSB-MP004938HU(F1) CD44 Mammalian cell C-terminal hFc-tagged
Recombinant Human Leukocyte surface antigen CD47 (CD47), partial (Active) CSB-MP004940HU CD47 Mammalian cell C-terminal hFc-tagged
Recombinant Human Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) (E398K) (Active) CSB-MP005165HU CEACAM5 Mammalian cell C-terminal 10xHis-tagged
Recombinant Human Cytotoxic T-lymphocyte protein 4 (CTLA4), partial (Active) CSB-MP006163HU1 CTLA4 Mammalian cell C-terminal hFc-tagged
Recombinant Human Epidermal growth factor receptor (EGFR), partial (Active) CSB-MP007479HU EGFR Mammalian cell N-terminal 10xHis-tagged and C-terminal Myc-tagged
Recombinant Human Receptor tyrosine-protein kinase erbB-2 (ERBB2), partial (Active) CSB-MP007763HU ERBB2 Mammalian cell C-terminal 6xHis-tagged
Recombinant Human Receptor tyrosine-protein kinase erbB-3 (ERBB3), partial (Active) CSB-MP007765HU ERBB3 Mammalian cell C-terminal hFc-tagged
Recombinant Human Interleukin-2 (IL2) (Active) CSB-MP011629HU IL2 Mammalian cell N-terminal hFc-tagged
Recombinant Human Interleukin-2 receptor subunit alpha (IL2RA), partial (Active) CSB-MP011649HU3 IL2RA Mammalian cell C-terminal 10xHis-tagged
Recombinant Human Hepatocyte growth factor receptor (MET), partial (Active) CSB-MP013714HU MET Mammalian cell C-terminal hFc-tagged
Recombinant Human Mesothelin (MSLN), partial (Active) CSB-MP015044HUc9 MSLN Mammalian cell N-terminal hFc-tagged
Recombinant Human Mucin-16 (MUC16), partial (Active) CSB-MP704410HU3c7 MUC16 Mammalian cell C-terminal 6xHis-tagged
Recombinant Human Nectin-4 (NECTIN4), partial (Active) CSB-MP822274HU NECTIN4 Mammalian cell C-terminal 10xHis-tagged
Recombinant Human 5'-nucleotidase (NT5E) (Active) CSB-MP723415HU NT5E Mammalian cell C-terminal 6xHis-tagged
Recombinant Human Programmed cell death protein 1 (PDCD1), partial (Active) CSB-MP619964HU1 PDCD1 Mammalian cell C-terminal 6xHis-tagged

● 稳定细胞株

CSB-SC020067HU FACS

CT26/Human ROR1 Stable Cell Line

CSB-SC020067HU

Untransfected CT26 cells (green line) and transfected Human ROR1 CT26 stable cells (red line) were stained with anti-ROR1 antibody (CSB-RA020067A1HU) (2µg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

● 重组抗体

ERBB2 Recombinant Monoclonal Antibody
CSB-RA260392A0HU
CSB-RA260392A0HU IHC

IHC image of CSB-RA260392A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.

MET Recombinant Monoclonal Antibody
CSB-RA634199A0HU
CSB-RA634199A0HU IHC

IHC image of CSB-RA634199A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system.

CD44 Recombinant Monoclonal Antibody
CSB-RA292372A0HU
CSB-RA292372A0HU FC

Overlay Peak curve showing Hela cells surface stained with CSB-RA292372A0HU (red line) at 1:50.

EGFR Recombinant Monoclonal Antibody
CSB-RA159341A0HU
CSB-RA159341A0HU FC

Overlay histogram showing Jurkat cells stained with CSB-RA159341A0HU (red line) at 1:50.

产品名称 货号 靶点 反应种属 应用范围
CA9 Recombinant Monoclonal Antibody CSB-RA614990A0HU CA9 Human ELISA, IHC
CD247 Recombinant Monoclonal Antibody CSB-RA244537A0HU CD247 Human ELISA, FC
CD27 Recombinant Monoclonal Antibody CSB-RA953976A0HU CD27 Human ELISA, WB
CD274 Recombinant Monoclonal Antibody CSB-RA977797A0HU CD274 Human ELISA, WB, IHC
CD274 Recombinant Monoclonal Antibody CSB-RA878942MA1HU CD274 Human ELISA, IHC, FC
CD40 Recombinant Monoclonal Antibody CSB-RA004936MA1HU CD40 Human ELISA, IF, FC
CD44 Recombinant Monoclonal Antibody CSB-RA004938A0HU CD44 Human ELISA, WB, IHC
CD44 Recombinant Monoclonal Antibody CSB-RA292372A0HU CD44 Human ELISA, WB, IHC, IF, FC
CD44 Recombinant Monoclonal Antibody CSB-RA004938MA1HU CD44 Human ELISA, FC
CD47 Recombinant Monoclonal Antibody CSB-RA802124A0HU CD47 Human ELISA, WB, IHC, IF
CEACAM5 Recombinant Monoclonal Antibody CSB-RA005165MA3HU CEACAM5 Human ELISA, IF, FC
CEACAM5 Recombinant Monoclonal Antibody CSB-RA005165MA1HU CEACAM5 Human ELISA
CTLA4 Recombinant Monoclonal Antibody CSB-RA213310A0HU CTLA4 Human ELISA, IHC
CTLA4 Recombinant Monoclonal Antibody CSB-RA006163MA1HU CTLA4 Human, Mouse ELISA, WB, IF, FC
Phospho-EGFR (Y1092) Recombinant Monoclonal Antibody CSB-RA007479A1092phHU EGFR Human ELISA, WB
Phospho-EGFR (Y1068) Recombinant Monoclonal Antibody CSB-RA007479A1068phHU EGFR Human ELISA, WB
EGFR Recombinant Monoclonal Antibody CSB-RA159341A0HU EGFR Human ELISA, WB, IHC, IF, FC
EGFR Recombinant Monoclonal Antibody CSB-RA794061A0HU EGFR Human ELISA, WB, IHC
EGFR Recombinant Monoclonal Antibody CSB-RA159341MA1HU EGFR Human ELISA, IHC, FC
EPCAM Recombinant Monoclonal Antibody CSB-RA932207A0HU EPCAM Human ELISA, WB

● ELISA试剂盒

产品名称 货号 靶点 检测范围 灵敏度
Human Carbonic Anhydrase 9(CA9) ELISA Kit CSB-E13266h CA9 31.25 pg/mL-2000 pg/mL 7.81 pg/mL
Human T-cell surface glycoprotein CD3 zeta chain (CD247) ELISA kit CSB-EL004904HU CD247 0.156 ng/mL-10 ng/mL 0.039 ng/mL
Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit CSB-E13644h CD274 15.6 pg/mL-1000 pg/mL 3.9 pg/mL
Mouse Programmed cell death 1 ligand 1(CD274) ELISA kit CSB-EL004911MO CD274 31.25 pg/mL-2000 pg/mL 7.81 pg/mL
Human Soluble CD276,sCD276/sB7-H3 ELISA Kit CSB-E14285h CD276 3.12 ng/mL-200 ng/mL 0.78 ng/mL
Human soluble cluster of differentiation 28,sCD28 ELISA Kit CSB-E09296h CD28 0.625 ng/mL-40 ng/mL 0.156 ng/mL
Mouse Tumor necrosis factor receptor superfamily member 5(CD40) ELISA kit CSB-EL004936MO CD40 Request Information Request Information
Human cluster Of differentiation,CD44 ELISA Kit CSB-E11846h CD44 78 pg/mL-5000 pg/mL 19.5 pg/mL
Human Leukocyte surface antigen CD47(CD47) ELISA kit CSB-EL004940HU CD47 3.12 pg/mL-200 pg/mL 0.78 pg/mL
Mouse Leukocyte surface antigen CD47(CD47) ELISA kit CSB-EL004940MO CD47 15.6 pg/mL-1000 pg/mL 3.9 pg/mL
Human carcinoembryonic antigen,CEA ELISA Kit CSB-E04767h CEACAM5 5 ng/mL-120 ng/mL 2 ng/mL
Mouse carcinoembryonic antign,CEA ELISA Kit CSB-E13925m CEACAM5 62.5 pg/mL-4000 pg/mL 15.6 pg/mL
Human Macrophage Colony-Stimulating Factor Receptor,M-CSFR ELISA Kit CSB-E10012h CSF1R 0.156 ng/mL-10 ng/mL 0.039 ng/mL
Rat Macrophage colony-stimulating factor 1 receptor(CSF1R) ELISA kit CSB-EL006044RA CSF1R 0.312 ng/mL-20 ng/mL 0.078 ng/mL
Human Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit CSB-E04568h CSF2 15.6 pg/mL-1000 pg/mL 3.9 pg/mL
Mouse Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit CSB-E04569m CSF2 15.6 pg/mL-1000 pg/mL 3.9 pg/mL
Rat Granulocyte-Macrophage Colony Stimulating Factor,GM-CSF ELISA Kit CSB-E04570r CSF2 15.6 pg/ml - 1000 pg/ml 3.9 pg/ml
Human cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit CSB-E09171h CTLA4 125 pg/mL-8000 pg/mL 31.25 pg/mL
Mouse cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit CSB-E13637m CTLA4 0.312 ng/mL-20 ng/mL 0.078 ng/mL
Human epidermal growth factor receptor,EGFR ELISA Kit CSB-E12124h EGFR 0.312 ng/mL-20 ng/mL 0.019 ng/mL

参考文献:

1. Cell 186, April 13, 2023

2. Larissa A. Korde, Mark R. Somerfield, Dawn L. Hershman, et al. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. DOI: 10.1200/JCO.22.00503 Journal of Clinical Oncology

3. Lajos Pusztai, Carsten Denkert, Joyce O'Shaughnessy, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. J Clin Oncol 40, 2022 (suppl 16; abstr 503). DOI: 10.1200/JCO.2022.40.16_suppl.503

4. Breast cancer-WHO: https://www.who.int/news-room/fact-sheets/detail/breast-cancer